SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, phase II study evaluating the efficacy and safety of SHR-A1811 alone or in combination with Adebrelimab in Stage II-III HR Positive/HER2 Low Breast Cancer. Subjects will receive the neoadjuvant therapy of SHR-A1811 alone or in combination with Adebrelimab for six cycles, and then undergo surgery within 4 weeks after neoadjuvant therapy. Efficacy will be assessed every 2 cycles.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku od 18 do 75 lat
- •Potwierdzony histologicznie rak piersi HR+/HER2-Low
- •Pacjentka bez poprzedniego leczenia, stadium II-III
- •Dobry stan ogólny (ECOG 0-1)
- •Prawidłowa funkcja organów wewnętrznych
- •Dobra chęć uczestnictwa i możliwość regularnych wizyt kontrolnych
✗ Disqualifies
- •Wcześniejsze leczenie przeciwnowotworowe (chemioterapia, radioterapia, terapia celowana, hormonoterapia)
- •Jednoczesne leczenie innymi lekami przeciwnowotworowymi
- •Rak obu piersi, zapalny rak piersi lub ukryty rak piersi
- •Zaawansowany rak piersi (stadium IV)
- •Potwierdzony inny nowotwór w ostatnich 5 latach (poza niektórymi rodzajami raka skóry)
- •Uczestnictwo w innych badaniach klinicznych w ciągu ostatnich 4 tygodni
- •Znana alergia na składniki badanego leku
- •Poważne choroby serca lub problemy z krwawień
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- December 4, 2024
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Shengjing Hospital affiliated to China Medical University
Shenyang, China
Trial contact
Nan Niu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.